Rare diseases
Investigational molecules
Locations
Am Klopferspitz 19, Martinsried, 82152 Planegg, Germany
CatalYm GmbH focuses on clinical research in advanced-stage solid tumors and relapsed/refractory cancer, with activity across multiple difficult-to-treat settings.
The sponsor’s oncology portfolio also includes patients with prior anti-PD-1/PD-L1 treatment exposure and limited remaining standard options.
CatalYm GmbH runs clinical trials in conditions such as Cachexia, Hepatocellular carcinoma, Non-small cell lung cancer, Bladder cancer, among others.
Clinical trials run by this sponsor – those enrolling participants first.
A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is
BulgariaA study testing visugromab, nivolumab, and lenvatinib for patients with advanced liver cancer that cannot be removed by surgery after previous treatment failed
FranceStudy of visugromab and nivolumab with or without docetaxel as second-line treatment for patients with metastatic non-squamous non-small cell lung cancer
GermanyStudy of Visugromab and Nivolumab for Patients with Muscle-Invasive Bladder Cancer Who Cannot or Refuse Cisplatin Chemotherapy
ItalyStudy on CTL-002 and Nivolumab for Patients with Advanced-Stage, Relapsed/Refractory Solid Tumors
GermanyIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
